Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
The impact of a hematocrit of 20% during normothermic cardiopulmonary bypass for elective coronary artery bypass graft surgery on oxygen delivery and clinical outcome: a randomised controlled study
ISRCTN ISRCTN35655335
ClinicalTrials.gov identifier
Public title The impact of a hematocrit of 20% during normothermic cardiopulmonary bypass for elective coronary artery bypass graft surgery on oxygen delivery and clinical outcome: a randomised controlled study
Scientific title
Acronym krit hematocrit study
Serial number at source N/A
Study hypothesis To evaluate whether a hematocrit of 20% versus 25% during normothermic cardiopulmonary bypass for Coronary Artery Bypass Graft (CABG) surgery influences oxygen delivery and oxygen consumption.
Lay summary
Ethics approval Ethics approval received from the local medical ethics committee
Study design Randomised controlled trial
Countries of recruitment Germany
Disease/condition/study domain Coronary artery disease requiring surgical revascularisation
Participants - inclusion criteria Coronary artery disease patients to about to undergo coronary artery bypass graft surgery.
Participants - exclusion criteria 1. Ejection fraction less than 40%
2. Chronic Obstructive Pulmonary Disease (COPD)
3. Renal insufficiency
4. Peripheral artery disease
5. Hepatic dysfunction
Anticipated start date 01/02/2004
Anticipated end date 31/01/2005
Status of trial Completed
Patient information material
Target number of participants 60
Interventions Hemodilution during cardiopulmonary bypass achieving a hematocrit of 20% versus 25%.
Primary outcome measure(s) Oxygen delivery and oxygen consumption.
Secondary outcome measure(s) 1. Myocardial infarction
2. Renal insufficiency measured as creatinine and urine volume
3. Neurological deficits displayed as agitated arousal reactions and stroke
Sources of funding Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany) - institutional funding
Trial website
Publications 1. 2006 results in http://www.ncbi.nlm.nih.gov/pubmed/16606474
2. 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/19747406
Contact name Prof  Claudia  Spies
  Address Dept. of Anesthesiology and Intensive Care Medicine
Charite-University Hospital Berlin
Schumannstr. 20-21
  City/town Berlin
  Zip/Postcode 10098
  Country Germany
  Tel +49 (0)3045 053 1012
  Fax +49 (0)3045 053 1911
  Email claudia.spies@charite.de
Sponsor Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany)
  Address Department of Anesthesiology and Intensive Care Medicine
Schumannstr. 20-21
  City/town Berlin
  Zip/Postcode 10098
  Country Germany
  Tel +49 (0)3045 053 1012
  Fax +49 (0)3045 053 1911
  Email anaesth@charite.de
Date applied 11/01/2006
Last edited 29/03/2010
Date ISRCTN assigned 19/01/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central